Traditional inhibitors function by binding to mutant KRAS proteins and obstructing their activity, but this method often falls short as cancer cells evolve mechanisms to circumvent inhibition and resume proliferative signaling. Addressing this limitation, the new study pivots towards inducing the selective degradation of the mutant KRAS protein itself, rather than merely inhibiting its function. This strategy leverages Proteolysis Targeting Chimeras (PROTACs), an innovative drug class designed to co-opt the cell’s intrinsic protein degradation machinery, effectively “tagging” the oncogenic protein for proteasomal destruction.

However, no current PROTACs can directly engage KRAS^G12V, posing a significant challenge. To overcome this, the research team ingeniously engineered lung cancer cells to express KRAS^G12V appended with a molecular tag amenable to novel PROTACs developed in collaboration with chemical biology experts at IRB Barcelona. This innovative tagging allowed the precise recruitment of the degradation system, resulting in efficient elimination of the mutant KRAS protein in vivo.

Employing genetically modified mouse models harboring these tagged KRAS^G12V proteins, the researchers observed remarkable tumor regression upon PROTAC treatment. The lung adenocarcinomas regressed substantially, highlighting the tumor cells’ profound dependency on continuous KRAS^G12V signaling for survival and proliferation. This response was more robust and durable compared to outcomes previously reported with conventional KRAS inhibitors, suggesting that targeted proteolysis could represent a superior therapeutic avenue.

Intriguingly, the study also delineated the immune landscape following KRAS degradation. Although an increase in immune cell infiltration within treated tumors was documented, parallel experiments in immunodeficient mice confirmed that the initial tumor regression was predominantly driven by direct cancer cell-autonomous mechanisms rather than the immune system. This insight emphasizes the fundamental cytotoxic potential of mutant KRAS degradation, independent of adaptive immune activation.

Delving deeply into the mechanisms of acquired resistance, the scientists uncovered a resistance paradigm distinct from that encountered with kinase inhibitors. Instead of mutations within KRAS itself or reactivation of downstream oncogenic pathways, resistant tumors exhibited alterations in the cellular proteostasis machinery. These modifications impaired the effectiveness of the proteasomal degradation system, effectively sabotaging the molecular machinery required to dismantle mutant KRAS, thereby allowing the tumor cells to evade destruction.

This distinct resistance mechanism highlights an evolutionary pressure on tumors to preserve KRAS dependence while simultaneously overcoming the novel therapeutic approach. By dysregulating protein degradation pathways, cancer cells develop an unexpected mode of resistance, underscoring the complexity of targeted proteolysis as a therapeutic modality and the necessity for combination strategies or next-generation PROTACs that can circumvent this escape route.

The conception and execution of this work are the result of a highly collaborative endeavor, integrating expertise from molecular biology, chemical synthesis, and cancer pharmacology across institutions including IRB Barcelona, Centro de Investigación del Cáncer, University of Salamanca, University of Navarra, Catalan Institute of Oncology, University of Liège, University of Turin, CIBERONC, and University of Barcelona. The interdisciplinary nature of this research reinforces the value of collaborative networks in tackling the formidable challenge of KRAS-driven malignancies.

From a therapeutic development perspective, these findings signal the dawn of a new era in targeted cancer therapies. While KRAS inhibitors revolutionized treatment paradigms, the advent of targeted protein degradation represents a paradigm shift with potential transformative impacts on clinical outcomes. The prospect of deploying sequential or combinatorial regimens, integrating KRAS inhibition with degradation, could potentiate tumor control and circumvent the resistance that plagues monotherapy approaches.

Moreover, the tailored strategy of tagging mutant KRAS not only facilitates in vivo functional studies of KRAS degradation dynamics but also establishes a versatile platform to explore PROTAC efficacy against other oncogenic drivers traditionally deemed “undruggable.” This platform empowers future preclinical investigations and accelerates the translation of proteolysis-based therapeutics into clinical settings for diverse cancer types.

Support for this pioneering research was generously provided by the Spanish Ministry of Science and Innovation, the European Research Council (ERC), the Spanish Association Against Cancer (AECC), Generalitat de Catalunya, the European Union’s NextGenerationEU program, “la Caixa” Foundation, and Farmaindustria. Their commitment underscores the critical societal imperative of advancing cancer research toward curative therapies.

In summary, the strategic targeting of mutant KRAS through induced degradation via PROTAC technology represents a compelling advance, combining molecular innovation with therapeutic promise. This elegant approach not only deepens understanding of lung adenocarcinoma biology but also charts new directions for combating resistance, potentially heralding a future where devastating KRAS-driven cancers can be durably controlled or eradicated.

Subject of Research: Targeted degradation of mutant KRAS in lung adenocarcinoma using PROTAC technology and investigation of resistance mechanisms in vivo.

Article Title: Targeted KRASG12V degradation in vivo elicits lung adenocarcinoma regression with subsequent relapse from dysregulated proteolysis

News Publication Date: 27 May 2026

Image Credits: IRB Barcelona

Keywords: Lung cancer, KRAS mutation, oncogene, targeted protein degradation, PROTACs, drug resistance, lung adenocarcinoma, immunotherapy, cancer treatment, proteolysis, in vivo study, molecular tag

The pivotal insight into the design of these novel PROTACs emerged from a co-crystal structure analysis of a known bivalent PROTAC, MZ1. This molecular complex revealed how the interaction between the ligands and their respective targets is mediated by spatial arrangements which can be manipulated to increase valency. By employing macrocyclic structures, researchers aim to attain a more rigid and defined bioactive conformation, which consequently enhances the overall stability and function of the PROTAC. On the other hand, the trivalent PROTACs take a different approach, focusing on increasing the avidity and cooperativity of the PROTAC ternary complex by augmenting the number of binding sites available for the target protein.

The synthesis of these innovative PROTACs, dubbed macroPROTAC-1 and SIM1, follows a rigorous, step-by-step botanical approach. Researchers outline a well-planned synthetic pathway that not only details the generation of the macrocyclic and trivalent cores but also explores the precise conjugation methods to their respective ligands. This elaborate synthesis procedure emphasizes the necessity of maintaining precise control over the molecular architecture to ensure functional integrity.

The synthesis of macroPROTAC-1 is anticipated to be a 14-day endeavor, while the construction of SIM1 is predicted to take around 10 days. This meticulous timeframe underscores the complexity of the processes involved in creating these compounds, showcasing the advanced techniques that underpin modern chemistry. As researchers embark on this journey, they are met with numerous challenges that test their knowledge of organic chemistry, reaction mechanisms, and biophysical methods for characterizing the resulting molecules.

In addition to the synthesis, an integral aspect of the development process involves the biophysical and cellular evaluation of these next-generation PROTACs. This includes assessing how well each compound binds to its target and E3 ligase, as well as testing their efficacy in promoting protein degradation in living cells. Such evaluations are fundamental, as they provide crucial insights into the practicality and therapeutic potential of these molecules. Preliminary results suggest that the macrocyclic and trivalent designs confer advantages over traditional PROTACs, indicating improved specificity and reduced off-target effects.

Moreover, by employing rigorous negative control compounds, researchers can better assess the performance of macroPROTAC-1 and SIM1. These controls serve as benchmarks, illuminating the distinct advantages of the new designs and providing a comparative analysis that is essential for validating scientific rigor. This methodical approach exemplifies how innovative research can redefine existing boundaries in drug design and development, opening doors for effective therapeutic strategies against previously difficult-to-treat diseases.

The findings stemming from these proof-of-concept studies demonstrate not only the viability of more complex molecular constructs but also their potential to address unmet medical needs in various therapeutic areas. The rapid expansion of the PROTAC platform underscores a shift in chemical biology, encouraging novel explorations in ligand development, connectivity, and stability. As current studies evolve, it becomes increasingly clear that expanding beyond traditional approaches is essential for harnessing the full power of targeted protein degradation.

As the research community continues to delve into the synthesis and application of macrocyclic and trivalent PROTACs, the implications extend far beyond cancer treatment. Future applications may emerge across various other diseases, including neurodegenerative conditions and autoimmune disorders, as scientists better understand the intricacies of protein interactions and degradation pathways. The evolution of PROTAC technology promises a transformative legacy in the realm of medicinal chemistry that could lead to breakthroughs in our quest for precision medicine.

Innovations like macroPROTAC-1 and SIM1 exemplify how creativity in chemical design is unlocking new potentials. This journey of discovery integrates traditional synthetic methodologies with cutting-edge biophysical techniques, fostering an environment ripe for innovation. As researchers remain committed to pushing the boundaries of what is possible, the realm of targeted protein degradation stands on the cusp of a new era—one marked by comprehensive therapeutic options and improved quality of life for patients facing formidable health challenges.

Ultimately, the future of PROTAC research is not just about refining compounds but also about understanding the underlying mechanisms that will aid in creating next-generation therapies. As new discoveries emerge, they will not only enrich the scientific literature but will also pave the way for a more nuanced approach to drug design. The ongoing journey into the realm of macrocyclic and trivalent PROTACs will surely inspire future generations of scientists to challenge the status quo and explore the uncharted territories of biochemical innovation.

Technology-driven collaborations across academic and industry spheres will further amplify the efforts to translate these discoveries into therapeutic realities. The synthesis process of compounds like macroPROTAC-1 and SIM1 highlights the importance of interdisciplinary research, bringing together expertise in organic chemistry, structural biology, and pharmacology. This collaboration will likely accelerate the transition from concept to clinical application, ensuring that the potential of targeted protein degradation is fully realized in therapeutic settings.

As this pioneering research unfolds, it captures the spirit of modern scientific inquiry, emphasizing the importance of adaptability, creativity, and tenacity. In a landscape characterized by rapid advancement, the development of novel PROTACs presents a compelling case study in the convergence of science, innovation, and clinical need—ultimately illustrating how far we can go when science and creativity intersect.

In conclusion, the innovative approach to designing macrocyclic and trivalent PROTACs signifies a transformative advancement in therapeutic strategies. With a clear focus on synthetic methodology, structure-function relationships, and experimental validation, researchers are charting a promising course toward revolutionizing drug discovery and development. These efforts mark a decisive moment in the ongoing fight against disease, heralding a new age of precision therapy characterized by targeted actions and minimized side effects.

Through diligent research and collaborative efforts, the potential for macrocyclic and trivalent PROTACs to change the landscape of medicine is indeed on the horizon, promising not only to enhance our understanding of protein biology but also to improve patient outcomes in tangible, meaningful ways.

Subject of Research: Macrocyclic and Trivalent PROTACs

Article Title: Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs

Article References:

Cao, Y., Harris, A.L. & Ciulli, A. Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs.
Nat Protoc (2025). https://doi.org/10.1038/s41596-025-01283-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01283-0

Keywords: PROTACs, Macrocyclic, Trivalent, Targeted Protein Degradation, Drug Development.

Proteolysis targeting chimeras have rapidly emerged over the past decade as a revolutionary strategy, leveraging the cell’s own ubiquitin-proteasome system to selectively destabilize disease-causing proteins. Conventional PROTAC constructs generally consist of two ligands—one binding the target protein, the other recruiting an E3 ubiquitin ligase—joined by a flexible linker. This large molecular architecture, while revolutionary, introduces challenges like suboptimal pharmacokinetics and synthetic complexity. The novel linker-free PROTACs detailed by Zhang et al. depart from this paradigm, elegantly simplifying the molecular framework without sacrificing function.

At the heart of this innovation is the realization that the linker, historically viewed as indispensable for juxtaposing the target and the ubiquitin ligase, can in fact be eliminated through precise chemical design. By directly conjugating the binding motifs or integrating them into a smaller molecular scaffold, the research team achieved a minimalistic yet potent chimera. This design paradigm not only reduces the overall size of the PROTAC molecules but also potentially enhances cellular permeability and metabolic stability—critical parameters for drug development.

The implications for cancer therapy are profound. Oncoproteins such as mutant kinases, transcription factors, and epigenetic regulators notoriously evade traditional small-molecule inhibitors due to their structural characteristics or compensatory cellular mechanisms. By facilitating induced proximity between these refractory targets and the cellular degradation machinery, linker-free PROTACs offer a versatile platform to irreversibly eliminate pathological proteins at their source, rather than merely inhibiting their function. The target degradation approach inherently overcomes issues related to drug resistance stemming from target mutation or amplification.

Zhang and colleagues meticulously validated their design via comprehensive biochemical and cellular assays. They engineered various linker-free PROTAC variants targeting clinically relevant oncoproteins, demonstrating efficient and selective degradation in multiple human cancer cell lines. The degradation exhibited remarkable kinetics and dose dependencies, reflecting an optimized interaction landscape between the target, the PROTAC, and the recruited E3 ligase complex. Intriguingly, the potency often surpassed linker-containing analogs, underscoring the unique advantages conferred by the streamlined structure.

A particularly striking aspect of the study is the structural characterization accompanying the functional data. Leveraging high-resolution X-ray crystallography and cryo-electron microscopy, the team elucidated how the linker-free PROTACs orient the target and E3 ligase to form a stable ternary complex conducive to ubiquitination. These structural snapshots reveal novel allosteric effects contributing to binding affinity and cooperative interactions, paving the way for rational design of next-generation PROTACs with defined spatial arrangements that maximize efficacy.

Moreover, the work illustrates the modularity of the linker-free design, showcasing adaptability to a diverse array of E3 ligases beyond the commonly employed von Hippel-Lindau (VHL) and cereblon ligases. This expands the therapeutic window and opens new frontiers by exploiting ligases expressing tissue-specific or disease-enriched patterns. The ability to target distinct ligases with compact PROTACs may also mitigate potential off-target toxicity and adverse immune responses, key considerations in clinical translation.

Pharmacological profiling in animal models reinforced the translational potential of these novel compounds. Linker-free PROTACs administered in xenograft models of aggressive cancers exhibited pronounced tumor regression without significant systemic toxicities. The improved pharmacokinetic properties—such as enhanced bioavailability and longer circulation half-life—support the notion that molecular downsizing directly benefits in vivo performance, addressing a critical bottleneck in the PROTAC field.

Beyond oncology, the principles established through this linker-free PROTAC study invite wide-ranging applications. Diseases driven by aberrant protein function—including neurodegeneration, autoimmune disorders, and viral infections—stand to benefit from this precision proteolysis strategy. The research highlights an emerging paradigm where chemical biology converges with medicinal chemistry and structural insights to reimagine targeted therapeutics as dynamically tailored degraders rather than static inhibitors.

Critically, this work also sparks discussions around intellectual property and pharmaceutical development. The minimization of molecular complexity could streamline manufacturing, reduce costs, and accelerate regulatory acceptance. Nevertheless, the intricate chemistry and need for comprehensive safety evaluations remain hurdles before human clinical trials can take place. Still, the momentum generated by these findings invigorates the field and inspires further innovation in targeted protein degradation.

The study’s broader impact extends beyond the laboratory bench, galvanizing the scientific community to rethink molecular design principles for drug discovery in the post-inhibitor era. By effectively “disconnecting” from bulky linkers, Zhang et al. have charted a new course that reconciles potency, selectivity, and drug-like properties in next-generation PROTACs. This work exemplifies how molecular simplicity and mechanistic sophistication can coexist to yield powerful therapeutic agents.

Such advances invariably raise questions concerning resistance mechanisms. While the irreversible degradation of oncoproteins reduces the likelihood of classic resistance mutations, cancer cells’ genomic plasticity may induce compensatory pathways or E3 ligase downregulation. Ongoing research must therefore integrate these novel PROTACs into broader therapeutic regimens and combinational strategies to sustain long-term efficacy.

As the drug discovery arena grapples with targeting undruggable proteomes, the ability to rationally design linker-free PROTACs opens a new dimension of chemical space exploration. Harnessing artificial intelligence and machine learning to predict optimal molecular configurations stands as a natural next step, promising to expedite discovery pipelines and personalize medicine.

In an era where the boundaries between biology, chemistry, and computational innovation blur, this seminal work published by Zhang and colleagues not only propels PROTAC technology forward but also sparks a renaissance in targeted protein degradation research. The promise of linker-free PROTACs transcends current limitations, forging a potent weapon against oncoproteins and ultimately offering renewed hope in the battle against cancer.

Subject of Research: Development of linker-free PROTACs for targeted degradation of oncoproteins in cancer therapy.

Article Title: Linker-free PROTACs efficiently induce the degradation of oncoproteins.

Article References:

Zhang, J., Chen, C., Chen, X. et al. Linker-free PROTACs efficiently induce the degradation of oncoproteins.
Nat Commun 16, 4794 (2025). https://doi.org/10.1038/s41467-025-60107-7

Image Credits: AI Generated

Traditional drug design has predominantly relied on optimizing molecules to passively diffuse across cell membranes, a process largely dictated by Lipinski’s ‘Rule of 5’, which sets a molecular weight threshold of 500 daltons for optimal absorption. PROTACs, often exceeding 1,000 daltons, fall well above this limit, presenting a formidable barrier for effective cellular entry. The new technique exploits a naturally occurring protein called CD36, which is abundantly expressed on the surface of various cell types, including those in the intestine, skin, lungs, eyes, and certain brain cells. CD36 functions as a receptor facilitating the uptake of various molecules via endocytosis, a process by which cells internalize substances by engulfing them in vesicles.

By chemically engineering PROTAC molecules to actively engage the CD36 receptor, scientists have developed a strategy they term chemical endocytic medicinal chemistry (CEMC). This innovative approach turns the passive absorption paradigm on its head by harnessing the cell’s own uptake machinery to swallow large molecular drugs effectively. The results are striking: CD36-mediated delivery resulted in a 7.7 to 22.3-fold increase in intracellular drug concentration within cancer cells, leading to an up to 23-fold enhancement in therapeutic potency as demonstrated in rigorous preclinical studies published in the journal Cell.

The mouse model data reveal not only improved drug uptake but also a corresponding augmentation in tumor suppression without compromising the drug’s solubility or stability—two critical parameters for successful clinical application. This finding dispels previous concerns that enhancing cellular internalization might destabilize these large molecules or reduce their bioavailability. Instead, the CEMC strategy maintains these essential properties while ensuring that the active drug reaches its intracellular targets with unprecedented efficiency.

This advancement is particularly significant for the class of bRo5 molecules, which break the traditional ‘Rule of 5’ restrictions in medicinal chemistry and include various therapeutic agents beyond just PROTACs. PROTACs stand apart as unique targeted cancer therapies that work not by inhibiting enzymatic functions but by catalyzing the degradation of pathogenic proteins, effectively removing them from the cellular environment. This mode of action holds immense promise in combating drug resistance, a major challenge in oncology, as resistant tumors often evolve mechanisms to bypass enzymatic inhibitors but remain susceptible to protein degradation strategies.

The implications of CD36-mediated endocytosis extend well beyond oncology. While current attention is focused on PROTACs targeting cancer and neurodegenerative diseases like Parkinson’s disease, the underlying methodology could be universally applicable to many large, structurally complex therapeutic molecules previously deemed pharmacologically intractable. By opening the door to efficient intracellular delivery of these drugs, the study fosters new avenues for treating a variety of conditions that hinge on modulating protein expression or function inside cells.

Leading the charge to uncover CD36 as a key facilitator of drug internalization, Dr. Hong-yu Li from the University of Texas Health Science Center emphasized the paradigm shift heralded by this discovery. For decades, the scientific consensus held that molecules of this size could not cross membranes readily since the concept of endocytic uptake of chemically designed compounds was largely unexplored. The identification of CD36 as a receptor exploitable for drug entry has unlocked a previously inaccessible dimension of pharmacology, enabling researchers to optimize drug structures for receptor-mediated internalization rather than solely relying on membrane permeability.

The robustness of the findings is underscored by independent replication across the collaborative teams, including the work led by Dr. Zhiqiang Qin at the University of Arkansas Medical Sciences. Their collective research efforts confirm that this approach yields reproducible and significant improvements in drug performance, providing a strong foundation for the next phase of translational research and clinical development.

Despite the promising data, the authors caution that further extensive evaluations in clinical trials are required before CD36-mediated drug delivery can be widely implemented in patient care. These studies must ascertain the safety, efficacy, and pharmacokinetics in humans, as well as investigate possible off-target effects or immune responses arising from receptor engagement. Nevertheless, the prospect of converting previously ‘undruggable’ large molecules into viable therapeutics represents a transformative leap for drug discovery.

Beyond the mechanistic insight, this breakthrough also shifts the drug development focus from passive molecular optimization to harnessing intricate cellular processes. It paves the way for a future in which medicinal chemistry can systematically exploit receptor-mediated endocytosis, moving toward a more sophisticated and biologically integrated approach to drug design. Such strategies could herald a new era in which the molecular size and complexity of therapeutic agents are no longer insurmountable obstacles but deliberately tailored features to enhance receptor engagement and drug delivery.

Conventional cancer treatments, such as kinase inhibitors, target specific enzymatic activities within cancer cells but often fail to eliminate the proteins themselves, leaving residual functions that contribute to disease progression and therapeutic resistance. By contrast, PROTACs promote complete degradation of these proteins, thereby delivering a more comprehensive therapeutic effect and reducing the likelihood of resistance. By leveraging CD36 to increase the intracellular concentration of PROTAC drugs, this approach amplifies their ability to dismantle oncogenic proteins and impede tumor growth more effectively.

Eight oral PROTAC candidates are actively undergoing clinical trials, including a Phase 3 study evaluating one agent designed to degrade estrogen receptors in breast cancer. The ability to enhance PROTAC bioavailability through CD36 engagement could tremendously impact these ongoing trials and future drug pipelines, potentially increasing the success rates and broadening the applicability of protein-degrading therapies.

The multidisciplinary collaboration and generous support from major funding bodies such as the National Institutes of Health and the Cancer Prevention and Research Institute of Texas highlight the importance and high interest in developing next-generation treatment modalities. Together, these efforts signify a pivotal advancement with far-reaching consequences for medicinal chemistry, oncology, and beyond.

Ultimately, chemical endocytic medicinal chemistry stands as a beacon of innovation, propelling the drug discovery field toward overcoming size limitations and expanding the therapeutic toolbox with highly potent, large molecule drugs that can be efficiently internalized by cells. As research advances, this novel strategy holds the potential to not only improve patient outcomes in cancer but also transform treatment paradigms across various diseases driven by pathogenic proteins.

Subject of Research: Cells

Article Title: CD-36-mediated endocytosis of proteolysis-targeting chimeras

News Publication Date: April 17, 2025

Web References:
https://doi.org/10.1016/j.cell.2025.03.036

References:
Lin, H.-K., Li, H.-Y., Qin, Z., et al. "CD-36-mediated endocytosis of proteolysis-targeting chimeras," Cell, April 17, 2025.

Image Credits:
Duke University School of Medicine

Keywords:
Cancer medication, Surface proteins, Drug design, Cancer cells, Drug resistance, Drug therapy